THE PRESENT INVENTION REVEALS HUMAN RECOMBINANT ANTIBODIES THAT RECOGNIZE THE HUMAN VASCULAR ENDOTHELIUM GROWTH FACTOR A (VEGF-A), BLOCK ITS INTERACTION WITH THE VEGFR2 RECEPTOR, AND INTERFERE WITH ITS PROLIFERATIVE EFFECT IN VITRO AND PRO-ANGIOGENIC EFFECT IN VIVO. THE ANTIBODIES IDENTIFY AN EPITOPE ON HUMAN VEGF-A DIFFERENT FROM ANY OTHER PREVIOUSLY REPORTED, AND WERE OBTAINED BY COMBINING ONE IMMUNOGLOBULIN LIGHT CHAIN VARIABLE REGION WITH OTHER THREE HEAVY CHAIN ONES. THE ANTIBODIES WERE OBTAINED BY HUMAN IMMUNOGLOBULIN VARIABLE REGION MUTAGENESIS, AND CAN BE EMPLOYED FOR THE IMMUNOTHERAPY OF PATHOLOGICAL ENTITIES ASSOCIATED WITH AN INCREASE IN VASCULATURE, SUCH AS AGE-RELATED MACULAR DEGENERATION, CANCER, AND OTHERS.
